Stay updated on Dupilumab in Bullous Pemphigoid Adults Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page.

Latest updates to the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov record for the dupilumab bullous pemphigoid study is displayed with its study details, results, participation criteria, locations, and supporting documents.SummaryDifference100%

- Check7 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the page continued to show a 403 error.SummaryDifference0.2%

- Check14 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check21 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 error.SummaryDifference0.2%

- Check28 days agoChange DetectedThe site revision label changes from v3.7.0 to v3.7.1. The study page is displaying a 403 Forbidden error rather than trial details.SummaryDifference0.2%

- Check49 days agoChange DetectedA 403 Forbidden page is now shown, with a basic header including Home and Revision: v3.7.0; at the same time, a large set of study documents and content (e.g., SAP, IPD sharing, ICF, PDFs, and location data) was removed from the study record.SummaryDifference21%

Stay in the know with updates to Dupilumab in Bullous Pemphigoid Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page.